For patients considering Human Microbiota Therapy
If you are considering HMT therapy as a patient, you may inquire with your supervising medical physician or contact our medical advisory staff at the Hong Kong Digestive Health Centre.
Human Microbiota Therapy (HMT) has been used as a therapy for gastrointestinal diseases for decades, but only recently has become the object of focused study and application. Currently, fecal microbiota transplant or HMT is being used in dozens of countries around the world, including the US, UK, Australia and Israel, as a treatment for Clostridium Difficile infection (CDI). FMT is generally effective more than 90 percent of the time as a treatment for CDI. In the US, the FDA has allowed clinicians to provide FMT to recurrent C. difficile patients.
Currently, FMT is also being researched as a treatment for many gastrointestinal related diseases, including Inflammatory Bowel Disease (Crohn’s Disease, Ulcerative Colitis), Irritable Bowel Syndrome, and other chronic digestive diseases. Medical clinics and FMT treatment centers in the UK and Australia have reported cases of successfully treating these diseases and conditions.
The goal is to restore the gut bacteria imbalance – dysbiosis – therefore conditions which stem from or correlate to dysbiosis will respond best.
Gut related conditions
As a policy, the Asia Microbiota Bank does not endorse or support the use of Human Microbiota Transplant for the treatment of ex-gut (non-gut) related conditions. AMB does support the treatment of gut conditions in patients which also have a related condition or gut-mediated condition.
Conditions which have reported benefit in patients who have undergone HMT.